Fyn is an important molecule in cancer pathogenesis and drug resistance

Daniel Elias, Henrik Ditzel

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Fyn is a non-receptor tyrosine kinase that belongs to the Src family kinases (SFKs) which under normal physiological conditions is involved in signal transduction pathways in the nervous system, as well as the development and activation of T lymphocytes. In cancer, Fyn contributes to the development and progression of several cancer types through its involvement in the control of cell growth, death, morphogenic transformation and cellular motility. Enhanced expression and/or activation of Fyn is observed in various cancers, including melanoma, glioblastoma, squamous cell carcinoma, prostate and breast cancers. Recent studies have demonstrated the importance of Fyn in the resistance or susceptibility of cancer cells to some anti-cancer treatments. We have recently shown that Fyn is upregulated in tamoxifen-resistant breast cancer cell lines and demonstrated that it plays a key role in the resistance mechanism. Further, we found that the cellular localization of Fyn within cancer cells of primary ER+ breast tumor tissue may serve as a prognostic marker. Understanding the role of Fyn in initiation and progression of cancer and its contribution to resistance against anti-cancer therapeutic agents may facilitate the development and use of novel drugs targeting Fyn for better management of malignancies.
OriginalsprogEngelsk
TidsskriftPharmacological Research
Vol/bind100
Sider (fra-til)250-254
ISSN1043-6618
DOI
StatusUdgivet - 21. aug. 2015

Emneord

  • Fyn, cancer, Src family kinase, drug resistance

Citer dette

@article{89e5c13caa83461494daa9cf8817dd33,
title = "Fyn is an important molecule in cancer pathogenesis and drug resistance",
abstract = "Fyn is a non-receptor tyrosine kinase that belongs to the Src family kinases (SFKs) which under normal physiological conditions is involved in signal transduction pathways in the nervous system, as well as the development and activation of T lymphocytes. In cancer, Fyn contributes to the development and progression of several cancer types through its involvement in the control of cell growth, death, morphogenic transformation and cellular motility. Enhanced expression and/or activation of Fyn is observed in various cancers, including melanoma, glioblastoma, squamous cell carcinoma, prostate and breast cancers. Recent studies have demonstrated the importance of Fyn in the resistance or susceptibility of cancer cells to some anti-cancer treatments. We have recently shown that Fyn is upregulated in tamoxifen-resistant breast cancer cell lines and demonstrated that it plays a key role in the resistance mechanism. Further, we found that the cellular localization of Fyn within cancer cells of primary ER+ breast tumor tissue may serve as a prognostic marker. Understanding the role of Fyn in initiation and progression of cancer and its contribution to resistance against anti-cancer therapeutic agents may facilitate the development and use of novel drugs targeting Fyn for better management of malignancies.",
keywords = "Fyn, cancer, Src family kinase, drug resistance",
author = "Daniel Elias and Henrik Ditzel",
year = "2015",
month = "8",
day = "21",
doi = "10.1016/j.phrs.2015.08.010",
language = "English",
volume = "100",
pages = "250--254",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Heinemann",

}

Fyn is an important molecule in cancer pathogenesis and drug resistance. / Elias, Daniel; Ditzel, Henrik.

I: Pharmacological Research, Bind 100, 21.08.2015, s. 250-254.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Fyn is an important molecule in cancer pathogenesis and drug resistance

AU - Elias, Daniel

AU - Ditzel, Henrik

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Fyn is a non-receptor tyrosine kinase that belongs to the Src family kinases (SFKs) which under normal physiological conditions is involved in signal transduction pathways in the nervous system, as well as the development and activation of T lymphocytes. In cancer, Fyn contributes to the development and progression of several cancer types through its involvement in the control of cell growth, death, morphogenic transformation and cellular motility. Enhanced expression and/or activation of Fyn is observed in various cancers, including melanoma, glioblastoma, squamous cell carcinoma, prostate and breast cancers. Recent studies have demonstrated the importance of Fyn in the resistance or susceptibility of cancer cells to some anti-cancer treatments. We have recently shown that Fyn is upregulated in tamoxifen-resistant breast cancer cell lines and demonstrated that it plays a key role in the resistance mechanism. Further, we found that the cellular localization of Fyn within cancer cells of primary ER+ breast tumor tissue may serve as a prognostic marker. Understanding the role of Fyn in initiation and progression of cancer and its contribution to resistance against anti-cancer therapeutic agents may facilitate the development and use of novel drugs targeting Fyn for better management of malignancies.

AB - Fyn is a non-receptor tyrosine kinase that belongs to the Src family kinases (SFKs) which under normal physiological conditions is involved in signal transduction pathways in the nervous system, as well as the development and activation of T lymphocytes. In cancer, Fyn contributes to the development and progression of several cancer types through its involvement in the control of cell growth, death, morphogenic transformation and cellular motility. Enhanced expression and/or activation of Fyn is observed in various cancers, including melanoma, glioblastoma, squamous cell carcinoma, prostate and breast cancers. Recent studies have demonstrated the importance of Fyn in the resistance or susceptibility of cancer cells to some anti-cancer treatments. We have recently shown that Fyn is upregulated in tamoxifen-resistant breast cancer cell lines and demonstrated that it plays a key role in the resistance mechanism. Further, we found that the cellular localization of Fyn within cancer cells of primary ER+ breast tumor tissue may serve as a prognostic marker. Understanding the role of Fyn in initiation and progression of cancer and its contribution to resistance against anti-cancer therapeutic agents may facilitate the development and use of novel drugs targeting Fyn for better management of malignancies.

KW - Fyn, cancer, Src family kinase, drug resistance

UR - http://www.ncbi.nlm.nih.gov/pubmed/26305432

U2 - 10.1016/j.phrs.2015.08.010

DO - 10.1016/j.phrs.2015.08.010

M3 - Journal article

VL - 100

SP - 250

EP - 254

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -